Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sunmax Biotechnology Co., Ltd. (4728:TWSE), powered by AI.
Sunmax Biotechnology Co., Ltd. is currently trading at $375.50. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sunmax Biotechnology Co., Ltd. on Alpha Lenz.
View Sunmax Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.
“Sunmax Biotechnology Co., Ltd.'s ROE is 46.4%. Explore profitability and growth together.”
Ask for details →Sunmax Biotechnology Co., Ltd. is a biomedical company specializing in the development, manufacturing, and commercialization of collagen-based medical devices and bio-surgical products. Established in 2001 and headquartered in Tainan, Taiwan, its core offerings focus on medical products and biomedical materials for both therapeutic and aesthetic applications, including dermal fillers, absorbable collagen membranes, dental bone grafts, and collagen bone fillers. The company's product lines also extend to skincare solutions such as moisturizing creams and facial masks, primarily leveraging biomedical-grade collagen for enhanced efficacy. Sunmax targets the healthcare and biotechnology sectors, with solutions utilized in medical procedures, cosmetic treatments, and dental surgeries. Its products, often branded under the Sunmax name, are distributed across Taiwan, Mainland China, and various international markets. Renowned for strong profitability metrics and robust returns on capital, Sunmax Biotechnology plays a significant role in advancing medical specialties by delivering high-quality collagen implants and materials tailored for both clinical and consumer health needs.
“Sunmax Biotechnology Co., Ltd.'s ROE is 46.4%. Explore profitability and growth together.”
Ask for details →Sunmax Biotechnology Co., Ltd. (ticker: 4728) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 375.5 with a P/E ratio of -x and P/B of -x.
ROE is 46.36% and operating margin is 49.27%. Annual revenue is $2.0B.